Ariana Pharmaceuticals SA

Core Technology: KEM® (Knowledge Extraction and Management)

Ariana Pharma???s foundational product is the KEM® (Knowledge Extraction and Management) platform. KEM® is described as the most advanced eXplainable AI platform, built upon a mathematical framework known as Galois Lattices, also referred to as Formal Concept Analysis (FCA). This technology is the culmination of over 15 years of development by experts in Machine Learning, Statistics, Biology, and drug development.

Key Features and Differentiators of KEM®:

• Explainability: The platform???s unique eXp.AI architecture reduces billions of data relationships into a manageable number of concise, logical implications, or "signatures," that are easily interpretable and can be challenged by human experts. This provides transparent, auditable results, a crucial factor for regulatory acceptance.
• Total Data Exploration: KEM® employs association rules to systematically and completely explore complex, high-dimensional datasets. This allows it to reveal hidden signals, complex relationships, and novel hypotheses that often go undetected by conventional statistical or numerical machine learning methods. The approach is both complementary to and supported by statistical analyses, ensuring robust and reproducible results.
• Robustness: KEM® is less sensitive to common dataset challenges, such as class imbalance (positives vs. negatives) and situations where the number of descriptors far exceeds the number of samples, a frequent issue in clinical and biomarker research.
• Data Integration: The platform is engineered to seamlessly analyze and integrate a diverse range of complex data types, including clinical characteristics, imaging data, metabolic profiles, biochemical readouts, Next-Generation Sequencing (NGS) and other multi-omic data (DNA, RNA, etc.), immunological readouts (like FACS), microbiota data, Patient Reported Outcomes (PROs), and Real-World Evidence (RWE) data. The company has access to a knowledge base containing over 160 million RWE records.

Products and Services

Ariana Pharma's business model is centered on deploying the KEM® platform through service partnerships and nonexclusive licensing to pharmaceutical and biotechnology companies. The company's services provide critical decision-support and data mining solutions across the drug development lifecycle, from preclinical research through to late-stage clinical trials and regulatory strategy.

Primary Services and Applications:

1. Precision Medicine and Clinical Trial Design:

   • Patient Stratification and Biomarker Discovery: Ariana is a leader in identifying effective biomarker signatures for personalized medicine. KEM® systematically explores combinations of biomarkers to maximize patient coverage and identify unique patient subgroups, even from small patient cohorts.
   • Clinical Protocol Optimization: The platform informs the design of precision medicine clinical protocols, which can be deployed in early-stage trials or in re-analyzing past clinical trials.
   • Response Prediction: Identifying the best responders to a therapeutic agent based on their individual biological characteristics.

2. Drug Development Optimization and Insight:

   • Optimal Drug Parameters: Identifying the optimal dose for a drug.
   • Efficacy Endpoints: Determining the most appropriate clinical endpoints and surrogate endpoints.
   • Combination Therapies: Discovering synergistic drug combinations.
   • Novel Indications: Uncovering new therapeutic applications for existing drugs.

3. Regulatory Strategy and Approval:

   • FDA-Validated Technology: KEM® is a highly validated technology, notably being the only FDA-reviewed technology that systematically explores biomarker combinations. The FDA has previously implemented the KEM platform to facilitate data analysis for the validation of biomarker signatures within its Voluntary Exploratory Data Submission (VXDS) program.
   • Accelerated Approval: By combining advanced data analytics with regulatory expertise, Ariana helps partners translate KEM findings into optimal regulatory strategies for accelerated drug approval.

Key Product Offering:

• Onco KEM®: A specialized, clinically tested application of the KEM® platform focused on oncology. Onco KEM® serves as a highly advanced treatment selection system, specifically designed to aid in critical therapeutic decisions for cancer patients. The platform has been applied to a wide variety of therapeutic areas, including neurodegenerative diseases and non-small-cell lung cancer (NSCLC) immunotherapy.

In summary, Ariana Pharmaceuticals SA is not a traditional drug maker, but a high-technology service provider whose central function is to leverage its KEM® eXplainable AI to extract actionable, verifiable, and regulatory-compliant insights from complex biological and clinical data. This service fundamentally aids its pharmaceutical partners in accelerating timelines, reducing development costs, and de-risking the path toward bringing personalized medicines to market.